T cell lymphotropic virus

Cornblath DR, Hoke A (2006) Recent advances in HIV neuropathy. Curr Opin Neurol 19(5) 446-450 Cornblath DR, McArthur JC (1988) Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex. Neurology 38(5) 794-796 Cornblath DR, McArthur JC et al (1987) Inflammatory demyeUnating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol 21(l) 32-40 Corral I, Quereda C et al (1997) Acute poly radiculopathies in HIV-infected patients. J Neurol 244(8) 499-504... 

The list of vimses involved in other human cancers includes hepatitis B, which is associated with hepatocellular carcinoma human papilloma viruses with cervical, penile and some anal carcinomas human T-cell lymphotropic virus type 1 associated with adult T-cell leukaemia/lymphoma syndrome and HIV with Kaposi s sarcoma. 

The acquired immune deficiency syndrome (AIDS) has become a serious public health problem around the world, and commands much concern in medical and lay circles alike. Its causative agent is a human T-cell lymphotropic virus (HIV) that destroys helper/inducer T cells (discussed in chapter 6) of the immune system and causes mortality by allowing opportunistic infections and malignancies. A compound designed along traditional lines, 3 -azido-3 -deoxythymidine (9.16, AZT), emerged as one of the first useful therapeutics. However, since that time many other drugs have been devised. 

Human Immunodeficiency Viruses and Human T-Cell Lymphotropic Viruses 1996 424 pages... 

Comparison of the activity of sulfated homopolysaccharides such as dextran and cellulose esters with that of neutral homopolysaccharides and sulfated heteropolysaccharides such as heparin and heparan sulfuric acid half esters shows potent virucidal activity against human T-cell lymphotropic virus type III (HTLV-III) for the sulfated homopolysaccharides. In contrast, neutral homopolysaccharides have no effect and sulfated heteropolysaccharides exhibit only a little effect on HTLV-III activities. This suggests that the sulfate moiety and the type of polysaccharide are most important in inhibiting growth of HTLV-III [126]. 

Bieganowska K, Hollsberg P, Buckle GJ, Lim DG, Greten TF, Schneck J, Altman JD, Jacobson S, Ledis SL, Hanchard B, Chin J, Morgan O, Roth PA, Hafler DA (1999) Direct analysis of viral-sjjecific CD8+ T cells with soluble HLA-A2Araxll—19 tetramer complexes in padents with human T cell lymphotropic virus-associated myelopathy. J Immunol 162 1765—1771. 

Calatdni S, Chevalier SA, Duprez R, Bassot S, Froment A, Mahieux R, Gessain A (2005) Discovery of a new human T-cell lymphotropic virus (HTLV-3) in Cend al Africa. Retrovirology 2 30. 

Elovaara I, Kcerrig S, Brewah AY, Woods RM, Lehky T, Jacobson S (1993) High human T cell lymphotropic virus type 1 (HTLV-l)-specific precursor cytotoxic T lymphocyte frequencies in padents with HTLV-1-associated neurological disease. J Exp Med 177 1567-1573. 

Hanoi E, Sdnchcombe JC, Saito M, AsquidiBE, Taylor GP, Tanaka Y, Weber JN, Giiffidis GM, Bangham CR (2000a) Eratricide among CD8(+) T lymphocytes naturally infected widi human T cell lymphotropic virus type I. Immunity 13 657—664. 

Jeffery KJ, Siddiqui A A, Bunce M, Lloyd AL, Vine AM, Witkover AD, Izumo S, Usuku K, Welsh KI, Osame M, Bangham CR (2000) The influence of HLA class I alleles and heterozygosity on die outcome of human T cell lymphotropic virus type I infecdon. J Immunol 165 7278-7284. 

Sakai JA, Nagai M, Brennan MB, Mora CA, Jacobson S (2001) hi vitro spontaneous lymphoproliferadon in padents widi human T-cell lymphotropic virus type I-associated neurologic disease Predominant expansion of CD8-I- T cells. Blood 98 1506-1511. 

Akizuki S, Yoshida S, Setoguchi M (1989) The neuropathyology of human T cell lymphotropic virus type I associated myelopathy. In HTLV-I and the Nervous System (Roman GC, Vemant JC, Osame M, eds), pp 253-260. New York R. Alan Liss. 

Furukawa K, Mori M, Ohta N, Ikeda H, Shida H, Furukawa K, Shiku H (1994) Clonal expansion of CD8+ cytotoxic T lymphocytes against human T cell lymphotropic virus type I (HTLV-I) genome products in HTLV-I-associated myelopathy/tropical spastic paraparesis patients. J Clin Invest 94 1830-1839. 

C, Dhib-Jalbut S, McFarland HF, Jacobson S (1996) Human T-cell lymphotropic virus type Il-associated myelopathy Clinical and immunologic profiles. Ann Neurol 40 714-723. 

Yamano Y, Nagai M, Brennan M, Mora CA, Soldan SS, Tomaru U, Takenouchi N, Izumo S, Osame M, lacohson S (2002) Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) ruRNA with proviral DNA load, virus-specific CD8(-i-) T cells, and disease severity in HTLV-l-associated myelopathy (HAM/TSP). Blood 99 88-94. 

Schreiber, G.B. Murphy, E.L. Horton, J.A. Wright, D.J. Garfein, R. Chien, H.C. Nass, C.C. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in Blood donors the retrovirus epidemiology donor study. J. Acquir. Defic. Syndr. Hum. Retrovirus 1997, 14, 263-271. 

HTLV-1 and HTLV-2 The human T cell lymphotropic virus type I (HTLV-I) is endemic in some areas of Japan, the Caribbean, and Africa, and has been associated with adult T cell leukemia. In Japan, seroconversion has been observed when anti-HTLV-I-negative patients were transfused with seropositive blood or blood components in one study the conversion rate was 62% (177). However, no case of transfusion-associated adult T cell leukemia has been reported to date (184,185). HTLV-II was originally isolated from a patient with hairy cell leukemia, but... 

HTLV-1 = Human T-cell Lymphotropic Virus type 1... 

HTLV, human T cell lymphotropic virus MALT, mucosa-associated lymphoid tissue NK, natural killer WHO, World Health Organization. 

---